TREATMENT OF CHRONIC LYMPHOCYTIC B-LEUKEMIA (B-CLL) WITH HUMAN IL-2 AND CD40

用人 IL-2 和 CD40 治疗慢性淋巴细胞 B 白血病 (B-CLL)

• 批准号: 7605939
• 负责人: MALCOLM K. BRENNER
• 金额: $ 0.32万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605939
• 关键词: Antigen Presentation; Autologous; CD40 Ligand; Cells; Chronic; Chronic Lymphocytic Leukemia; Computer Retrieval of Information on Scientific Projects Database; Data; Funding; Grant; Human; Immune response; Institution; Interleukin-2; Lymphocyte; Malignant - descriptor; Natural Killer Cells; Patients; Recruitment Activity; Research; Research Personnel; Resources; Safety; Source; Subcutaneous Injections; T-Lymphocyte; TNFRSF5 gene; Timor; Treatment Protocols; United States National Institutes of Health; abstracting; in vivo; leukemia; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ABSTRACT I. HYPOTHESIS It is proposed that the ability of CD40 Ligand (CD40L) to enhance leukemia antigen presentation in vivo, to act as a co-stimulator molecule and to induce hIL-2 release all serve to recruit both specific T cell and NK cell anti-leukemia effector mechanisms, which hIL-2 is then able to further amplify. II. SPECIFIC AIMS - To determine the safety of three to six subcutaneous (SC) injections of autologous malignant B cells from chronic lymphocytic leukemia (B-CLL) patients, which have been modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L). - To determine whether MHC-restricted or unrestricted anti-tumor immune responses are induced by SC injections of B-CLL cells which have been modified ex vivo to secrete hIL-2 and to express hCD40L. - To obtain preliminary data on the anti-timor effects of this treatment regimen.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 抽象的 I.假设 有人提出，CD40配体（CD40L）在体内增强白血病抗原表现的能力，充当共刺激剂分子并诱导HIL-2释放的能力，所有这些都可以募集特定的T细胞和NK细胞抗血清血症抗血症抗血症效应机制，然后HIL-2可以进一步放大这种HIL-2。 ii。 具体目标 - 确定来自慢性淋巴细胞性白血病（B-CLL）患者的三到六名皮下（SC）注射自体恶性B细胞的安全性，这些患者已被修饰，以分泌人介菌-2（HIL-2）和表达人CD40液体（HCD40L）。 - 确定MHC限制或不受限制的抗肿瘤免疫反应是由SC注射B-CLL细胞的诱导的，这些B-CLL细胞已被修饰以分泌HIL-2并表达HCD40L。 - 获取有关该治疗方案抗高速学作用的初步数据。